Allergen-specific immunotherapy of allergy and asthma: current and future trends.

Details

Serval ID
serval:BIB_CF19BFEC7031
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Allergen-specific immunotherapy of allergy and asthma: current and future trends.
Journal
Expert Review of Respiratory Medicine
Author(s)
Spertini F., Reymond C., Leimgruber A.
ISSN
1747-6356 (Electronic)
ISSN-L
1747-6348
Publication state
Published
Issued date
2009
Volume
3
Number
1
Pages
37-51
Language
english
Notes
Publication types: Journal ArticlePublication Status: ppublish
Abstract
Allergen-specific immunotherapy is the only immunomodulatory and etiological therapy of allergy and asthma. Conventional specific immunotherapy (SIT) with whole-allergen extract is antigen specific, effective on multiple organs, efficient on asthma in defined conditions, provides long-lasting protection and is cost effective. Moreover, SIT is able to prevent the course of rhinitis to asthma. SIT has its drawbacks: the long duration of treatment, the unsatisfactory standardization of allergen extracts and a questionable safety level. Novel approaches are aimed at drastically reducing adverse anaphylactic events, shortening the duration of therapy and improving its efficacy. Novel promising approaches have based their formulation on a limited set of recombinant allergens or chimeric molecules as well as on hypoallergenic allergen fragments or peptides. The simultaneous use of adjuvants with immunomodulatory properties may contribute to improve both the safety and efficacy of allergen-SIT of allergy and asthma.
Pubmed
Create date
11/09/2011 13:39
Last modification date
20/08/2019 15:49
Usage data